These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Amelioration of benzo (a) pyrene-induced lung carcinogenesis in strain A mice by diphenylmethyl selenocyanate.
    Author: Das RK, Banerjee S, Bhattacharya S.
    Journal: Exp Toxicol Pathol; 2007 Apr; 58(5):351-60. PubMed ID: 17178216.
    Abstract:
    Organoselenocyanates are an important class of chemopreventive agents, which possess antioxidative, antimutagenic and anticarcinogenic properties. In the present study, we used benzo (a) pyrene (BP)-induced lung carcinogenesis model for assessment of the chemopreventive efficacy of diphenylmethyl selenocyanate, a synthetic organoselenocyanate. BP was given at a dose of 0.2mg/mouse to initiate lung carcinogenesis in strain A mouse and the Se compound was given orally at a dose of 3mg/kgb.w. Histopathological characterizations and biochemical estimation were done to determine the protective effect of Se compound during the progression of lung carcinogenesis. Hyperplasia and severe dysplasia, the precancerous stage, were evident in carcinogen control group after 8th and 22nd week, respectively. These times were selected as the targets for chemoprevention. Treatment with the Se compound effectively reduced the incidence of hyperplasia and severe dysplasia. The Se compound also significantly (p<0.01) reduced microsomal lipid peroxidation and induced glutathione-S-transferase activity in liver and lung when measured after 8th and 22nd week. Lung cancer is diagnosed in majority of cases only at a later stage. These findings will further strengthen the view on organoselenocyanate as an effective cancer chemopreventive agent against lung carcinogenesis when applied at the post-initiation phase.
    [Abstract] [Full Text] [Related] [New Search]